sj-docx-1-hpq-10.1177_13591053241245263 – Supplemental material for What motivates information (non-)seeking behaviors about a healthy diet?

Supplemental material, sj-docx-1-hpq-10.1177_13591053241245263 for What motivates information (non-)seeking behaviors about a healthy diet? by Yijia Zhu, Nour Zeid, Dominik J Leiner and Sebastian Scherr in Journal of Health Psychology</p

sj-docx-2-hpq-10.1177_13591053241245263 – Supplemental material for What motivates information (non-)seeking behaviors about a healthy diet?

Supplemental material, sj-docx-2-hpq-10.1177_13591053241245263 for What motivates information (non-)seeking behaviors about a healthy diet? by Yijia Zhu, Nour Zeid, Dominik J Leiner and Sebastian Scherr in Journal of Health Psychology</p

sj-docx-4-hpq-10.1177_13591053241245263 – Supplemental material for What motivates information (non-)seeking behaviors about a healthy diet?

Supplemental material, sj-docx-4-hpq-10.1177_13591053241245263 for What motivates information (non-)seeking behaviors about a healthy diet? by Yijia Zhu, Nour Zeid, Dominik J Leiner and Sebastian Scherr in Journal of Health Psychology</p

sj-docx-3-hpq-10.1177_13591053241245263 – Supplemental material for What motivates information (non-)seeking behaviors about a healthy diet?

Supplemental material, sj-docx-3-hpq-10.1177_13591053241245263 for What motivates information (non-)seeking behaviors about a healthy diet? by Yijia Zhu, Nour Zeid, Dominik J Leiner and Sebastian Scherr in Journal of Health Psychology</p

Image_4_Effect of serum autoantibodies on the COVID-19 patient’s prognosis.PNG

ObjectivesVirus infection closely associated with autoimmune disease. The study aimed to explore the autoantibody profiles and the correlation of autoantibodies with the disease severity and the prognosis of the coronavirus disease 2019 (COVID-19) patients.MethodsThree hundred thirty-seven hospitalized COVID-19 patients from 6th to 23rd January 2023 were enrolled. Logistic and Cox regression analyses were used to analyze the risk factors for the patient’s disease severity and outcome. The association between Anti-extractable nuclear antigen antibody (ENA) positivity and the prognosis of COVID-19 patients was analyzed using Kaplan–Meier survival curves.Results137 of COVID-19 patients were detected positive for antinuclear antibody (ANA), 61 had positive results for ENA, and 38 were positive for ANA and ENA. ANA positivity rate was higher in non-severe illness group (p = 0.032). COVID-19 patients who died during hospitalization had a high rate of ENA positivity than convalescent patients (p = 0.002). Multivariate logistic regression showed that ANA positivity was a protective factor for the disease severity of COVID-19. Multivariate Cox regression analysis revealed that ENA positivity, white blood cells count (WBC), aspartate aminotransferase (AST), Creatinine (CREA), and CRP were independent risk factors for the outcome of COVID-19 patients, and that COVID-19 patients with ENA positivity had a lower cumulative survival rate (p = 0.002).ConclusionA spectrum of autoantibodies were expressed in COVID-19 patients, among which ANA and ENA positivity was associated with the severity and prognosis of COVID-19. Therefore, autoantibodies may help to assess the disease severity and prognosis of COVID-19 patients.</p

Table_1_Effect of serum autoantibodies on the COVID-19 patient’s prognosis.DOCX

ObjectivesVirus infection closely associated with autoimmune disease. The study aimed to explore the autoantibody profiles and the correlation of autoantibodies with the disease severity and the prognosis of the coronavirus disease 2019 (COVID-19) patients.MethodsThree hundred thirty-seven hospitalized COVID-19 patients from 6th to 23rd January 2023 were enrolled. Logistic and Cox regression analyses were used to analyze the risk factors for the patient’s disease severity and outcome. The association between Anti-extractable nuclear antigen antibody (ENA) positivity and the prognosis of COVID-19 patients was analyzed using Kaplan–Meier survival curves.Results137 of COVID-19 patients were detected positive for antinuclear antibody (ANA), 61 had positive results for ENA, and 38 were positive for ANA and ENA. ANA positivity rate was higher in non-severe illness group (p = 0.032). COVID-19 patients who died during hospitalization had a high rate of ENA positivity than convalescent patients (p = 0.002). Multivariate logistic regression showed that ANA positivity was a protective factor for the disease severity of COVID-19. Multivariate Cox regression analysis revealed that ENA positivity, white blood cells count (WBC), aspartate aminotransferase (AST), Creatinine (CREA), and CRP were independent risk factors for the outcome of COVID-19 patients, and that COVID-19 patients with ENA positivity had a lower cumulative survival rate (p = 0.002).ConclusionA spectrum of autoantibodies were expressed in COVID-19 patients, among which ANA and ENA positivity was associated with the severity and prognosis of COVID-19. Therefore, autoantibodies may help to assess the disease severity and prognosis of COVID-19 patients.</p

Image_2_Effect of serum autoantibodies on the COVID-19 patient’s prognosis.PNG

ObjectivesVirus infection closely associated with autoimmune disease. The study aimed to explore the autoantibody profiles and the correlation of autoantibodies with the disease severity and the prognosis of the coronavirus disease 2019 (COVID-19) patients.MethodsThree hundred thirty-seven hospitalized COVID-19 patients from 6th to 23rd January 2023 were enrolled. Logistic and Cox regression analyses were used to analyze the risk factors for the patient’s disease severity and outcome. The association between Anti-extractable nuclear antigen antibody (ENA) positivity and the prognosis of COVID-19 patients was analyzed using Kaplan–Meier survival curves.Results137 of COVID-19 patients were detected positive for antinuclear antibody (ANA), 61 had positive results for ENA, and 38 were positive for ANA and ENA. ANA positivity rate was higher in non-severe illness group (p = 0.032). COVID-19 patients who died during hospitalization had a high rate of ENA positivity than convalescent patients (p = 0.002). Multivariate logistic regression showed that ANA positivity was a protective factor for the disease severity of COVID-19. Multivariate Cox regression analysis revealed that ENA positivity, white blood cells count (WBC), aspartate aminotransferase (AST), Creatinine (CREA), and CRP were independent risk factors for the outcome of COVID-19 patients, and that COVID-19 patients with ENA positivity had a lower cumulative survival rate (p = 0.002).ConclusionA spectrum of autoantibodies were expressed in COVID-19 patients, among which ANA and ENA positivity was associated with the severity and prognosis of COVID-19. Therefore, autoantibodies may help to assess the disease severity and prognosis of COVID-19 patients.</p

Image_1_Effect of serum autoantibodies on the COVID-19 patient’s prognosis.PNG

ObjectivesVirus infection closely associated with autoimmune disease. The study aimed to explore the autoantibody profiles and the correlation of autoantibodies with the disease severity and the prognosis of the coronavirus disease 2019 (COVID-19) patients.MethodsThree hundred thirty-seven hospitalized COVID-19 patients from 6th to 23rd January 2023 were enrolled. Logistic and Cox regression analyses were used to analyze the risk factors for the patient’s disease severity and outcome. The association between Anti-extractable nuclear antigen antibody (ENA) positivity and the prognosis of COVID-19 patients was analyzed using Kaplan–Meier survival curves.Results137 of COVID-19 patients were detected positive for antinuclear antibody (ANA), 61 had positive results for ENA, and 38 were positive for ANA and ENA. ANA positivity rate was higher in non-severe illness group (p = 0.032). COVID-19 patients who died during hospitalization had a high rate of ENA positivity than convalescent patients (p = 0.002). Multivariate logistic regression showed that ANA positivity was a protective factor for the disease severity of COVID-19. Multivariate Cox regression analysis revealed that ENA positivity, white blood cells count (WBC), aspartate aminotransferase (AST), Creatinine (CREA), and CRP were independent risk factors for the outcome of COVID-19 patients, and that COVID-19 patients with ENA positivity had a lower cumulative survival rate (p = 0.002).ConclusionA spectrum of autoantibodies were expressed in COVID-19 patients, among which ANA and ENA positivity was associated with the severity and prognosis of COVID-19. Therefore, autoantibodies may help to assess the disease severity and prognosis of COVID-19 patients.</p

Image_3_Effect of serum autoantibodies on the COVID-19 patient’s prognosis.PNG

ObjectivesVirus infection closely associated with autoimmune disease. The study aimed to explore the autoantibody profiles and the correlation of autoantibodies with the disease severity and the prognosis of the coronavirus disease 2019 (COVID-19) patients.MethodsThree hundred thirty-seven hospitalized COVID-19 patients from 6th to 23rd January 2023 were enrolled. Logistic and Cox regression analyses were used to analyze the risk factors for the patient’s disease severity and outcome. The association between Anti-extractable nuclear antigen antibody (ENA) positivity and the prognosis of COVID-19 patients was analyzed using Kaplan–Meier survival curves.Results137 of COVID-19 patients were detected positive for antinuclear antibody (ANA), 61 had positive results for ENA, and 38 were positive for ANA and ENA. ANA positivity rate was higher in non-severe illness group (p = 0.032). COVID-19 patients who died during hospitalization had a high rate of ENA positivity than convalescent patients (p = 0.002). Multivariate logistic regression showed that ANA positivity was a protective factor for the disease severity of COVID-19. Multivariate Cox regression analysis revealed that ENA positivity, white blood cells count (WBC), aspartate aminotransferase (AST), Creatinine (CREA), and CRP were independent risk factors for the outcome of COVID-19 patients, and that COVID-19 patients with ENA positivity had a lower cumulative survival rate (p = 0.002).ConclusionA spectrum of autoantibodies were expressed in COVID-19 patients, among which ANA and ENA positivity was associated with the severity and prognosis of COVID-19. Therefore, autoantibodies may help to assess the disease severity and prognosis of COVID-19 patients.</p

Efficient Visible-Light-Driven CO₂ Methanation with Self-Regenerated Oxygen Vacancies in Co₃O₄/NiCo₂O₄ Hetero-Nanocages: Vacancy-Mediated Selective Photocatalysis

Surface atomic vacancies in semiconductor photocatalysts are highly attractive for improving catalysis efficiency and product selectivity, but the underlying mechanism of vacancy-mediated selectivity still remains ambiguous. By constructing a type of direct Z-scheme Co3O4/NiCo2O4 hetero-nanocage (HNC) that accommodates three kinds of possible oxygen vacancies (VOs), a comprehensive study was performed to unravel the roles of vacancies and demonstrate the mechanism of efficient visible-light-driven carbon dioxide (CO2) methanation. Upon light irradiation, efficient separation of charge carriers occurs in the Z-scheme Co3O4/NiCo2O4 HNCs, leading to the transfer of an electron to NiCo2O4. It has been identified for NiCo2O4 that only the vacancy VO2 over three cations (Co, Co, and Ni) at octahedral sites could facilitate the methanation process and possess the behavior of self-regeneration. Intriguingly, after the release of the product CH4 from NiCo2O4-VO2, the remaining oxygen (*O) favorably combines with protons and electrons to produce water molecules, and therefore, VO2 vacancies are regenerated, which significantly improves the durability of the methanation process. Besides, Ni atoms are found to be critical in initiating the CO2 methanation process by upshifting the d-band center of Co in NiCo2O4-VO2 toward the Fermi level and reducing the energy barrier of the *CHO intermediate. As a result, the main product of CO2 reduction is switched from CO for Co3O4 to CH4 for NiCo2O4, and the optimized photocatalyst exhibits an impressive single-carbon (C1) compound formation rate of 20.32 μmol g–1 h–1 and a high CH4 selectivity of up to 96.3%, outperforming the Co-/Ni-based photocatalysts. This work offers an in-depth insight into the precise atomic-level regulation of the photocatalytic selectivity and stability of Co3O4/NiCo2O4 HNCs and opens a path for the development of robust CO2 reduction photocatalysts